Advertisements
Feeds:
Posts
Comments

Search Results for 'tumor mutations'


My Cancer Genome from Vanderbilt University: Matching Tumor Mutations to Therapies & Clinical Trials Reporter: Aviva Lev-Ari, PhD, RN   GenomOncology Collaborates With Vanderbilt-Ingram Cancer Center for the Commercial Development of My Cancer Genome™ Tools February 10, 2014 Westlake, OH. February 10, 2014 – GenomOncology and Vanderbilt-Ingram Cancer Center (VICC) today announced a partnership for […]

Read Full Post »


Mutational Landscape of Rare Childhood Brain Cancer: Analysis of 60 Intercranial Germ Cell Tumor Cases using NGS, SNP and Expression Array Analysis – Signaling Pathways KIT/RAS are affected by mutations in IGCTs Reporter: Aviva Lev-Ari, PhD, RN With Omics Tools, Researchers Describe Mutational Landscape of Rare Childhood Brain Cancer June 04, 2014 By a GenomeWeb staff […]

Read Full Post »


Exome sequencing of serous endometrial tumors shows recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes Reporter and Curator: Dr. Sudipta Saha, Ph.D Endometrial cancer is the sixth most commonly diagnosed cancer in women worldwide, causing ~74,000 deaths annually. Serous endometrial cancers are a clinically aggressive subtype with a poorly defined genetic etiology2–4. Whole-exome […]

Read Full Post »


Recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes in serous endometrial tumors Reporter and Curator: Dr. Sudipta Saha, Ph.D. Endometrial cancer is the sixth most commonly diagnosed cancer in women worldwide, causing ~74,000 deaths annually1. Serous endometrial cancers are a clinically aggressive subtype with a poorly defined genetic etiology2–4. Whole-exome sequencing was used […]

Read Full Post »


Tumor Ammonia Recycling: How Cancer Cells Use Glutamate Dehydrogenase to Recycle Tumor Microenvironment Waste Products for Biosynthesis Reporter: Stephen J. Williams, PhD A feature of the tumorigenic process is the rewiring of the metabolic processes that provides a tumor cell the ability to grow and thrive in conditions of limiting nutrients as well as the […]

Read Full Post »


Evaluating the Genetic Profiles of Tumor Cells circulating in the Bloodstream could transform Cancer Care: A Blood Test for managing Lung Cancer @Stanford University Medical School Reporter: Aviva Lev-Ari, PhD, RN   A Legacy of Innovation @Stanford University Medical School 1967 First synthesis of biologically active DNA in test tube 1968 First adult human heart transplant […]

Read Full Post »


Cancer-free after immunotherapy treatment: Treating advanced colon cancer – targeting KRAS gene mutation by tumor-infiltrating lymphocytes (TILs) and Killer T-cells (NK) Reporter: Aviva Lev-Ari, PhD, RN   Based on By DENISE GRADY DEC. 7, 2016 Continue reading the main story http://www.nytimes.com/2016/12/07/health/cancer-immunotherapy.html?_r=0 The research involves cancer-fighting immune cells called tumor-infiltrating lymphocytes, or TILs. These are white blood […]

Read Full Post »


Pancreatic cancer tumorigenesis is neither gradual nor follows the accepted mutation order – A Study of changes in DNA copy number and their associated rearrangements in tumour-enriched genomes: Mitotic errors, consistent with punctuated equilibrium as the principal evolutionary trajectory.   Reporter: Aviva Lev-Ari, PhD, RN   I thank David Orchard-Webb, PhD for bringing to my attention […]

Read Full Post »


1:15 – 3:15 8/30 TUMOR NEOANTIGENS FOR PERSONALIZED IMMUNOTHERAPY @IMMUNO-ONCOLOGY SUMMIT – AUGUST 30-31, 2016 | Marriott Long Wharf Hotel – Boston, MA http://www.immuno-oncologysummit.com/uploadedFiles/Immuno_Oncology_Summit/Agenda/16/2016-The-Immuno-Oncology-Summit-Brochure.pdf     Leaders in Pharmaceutical Business intelligence (LPBI) Group covers in Real Time the IMMUNO-ONCOLOGY SUMMIT using Social Media Aviva Lev-Ari, PhD, RN, Founder, LPBI Group & Editor-in-Chief http://pharmaceuticalintelligence.com Streaming LIVE @ Marriott Long […]

Read Full Post »


Inactivation of an enzyme needed to metabolize glucose by Vitamic C deprives tumor cells of energy Reporter: Aviva Lev-Ari, PhD, RN     Vitamin C did kill cultured colon cancer cells with BRAF or KRAS mutations by raising free radical levels, which in turn inactivate an enzyme needed to metabolize glucose, depriving the cells of […]

Read Full Post »

Next »